August 2, 2011 – ZURICH (Reuters) – Actelion’s experimental multiple sclerosis drug ponesimod met its main goal in a mid-stage trial, giving the Swiss biotech’s pipeline a much-needed boost.
Actelion has had a bumpy ride after a string of product setbacks last year, and it has faced tough criticism from its main shareholder Elliott Advisors, which urged the group to consider putting itself up for sale.
Europe’s largest pure-play biotech group said on Tuesday its selective S1P1 receptor agonist, ponesimod, cut the number of new active inflammatory lesions in the brain in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews